The State Food and Drug Administration (SFDA) issued the No.53 Drug Administrative Protection Announcement on March 9, 2005, declaring the ending of drug administrative protection for Glaxo Wellcome GmbH & Co.'s Flixodisk  (fluticasone propionate dry powder inhaler).